Metraipolis › archive › dc_53343a8abe5f
Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada — Europe PMC PMID:41744849
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41744849
- DOI
- 10.3390/curroncol33020085
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T09:35:18.053Z
- SHA-256 of the archived text
a5a7e7b36321400a50c9990b6e3e043ae6af3912094ea98ad09ea32756f15a9a- Stable URL of this page
https://metraipolis.com/documento/dc_53343a8abe5f
How to cite
Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada — Europe PMC PMID:41744849 — Europe PMC (en), https://europepmc.org/article/MED/41744849 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_53343a8abe5f (Metraipolis archive dc_53343a8abe5f, sha256 a5a7e7b36321400a50c9990b6e3e043ae6af3912094ea98ad09ea32756f15a9a)
BibTeX
@misc{dc53343a8abe5f,
title = {Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada — Europe PMC PMID:41744849},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41744849},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_53343a8abe5f; sha256 a5a7e7b36321400a50c9990b6e3e043ae6af3912094ea98ad09ea32756f15a9a},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41744849. Agents can read the archived copy with the MCP tool read_document.